3,5-二甲基-1H-4-吡唑羧酸乙酯 | 35691-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3,5-二甲基-1H-4-吡唑羧酸乙酯
• 中文别名: 3,5-二甲基吡唑-4-甲酸乙酯
• 英文名称: 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester
• 英文别名: ethyl 3,5-dimethyl-1H-pyrazole-4-carboxylate；ethyl 3,5-dimethylpyrazole-4-carboxylate
• CAS: 35691-93-1
• 化学式: C₈H₁₂N₂O₂
• mdl: MFCD00159638
• 分子量: 168.195
• InChiKey: BCKARVLFIJPHQU-UHFFFAOYSA-N

物化性质

• 熔点：
  66 °C
• 沸点：
  284.8±35.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Name:	Ethyl 3 5-dimethyl-1H-4-pyrazolecarboxylate Material Safety Data Sheet
Synonym:
CAS:	35691-93-1

Section 1 - Chemical Product MSDS Name:Ethyl 3 5-dimethyl-1H-4-pyrazolecarboxylate Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
35691-93-1	Ethyl 3,5-dimethyl-1H-4-pyrazolecarbox	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 35691-93-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 95 - 96 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H12N2O2
Molecular Weight: 168.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 35691-93-1: UQ6394800 LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 3,5-dimethyl-1H-4-pyrazolecarboxylate - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 35691-93-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 35691-93-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 35691-93-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,5-二甲基-1H-4-吡唑羧酸乙酯 在 水 、 potassium hydroxide 作用下， 生成 3,5-二甲基-吡唑-4-羧酸
  参考文献：
  名称：

  The Structure and Dynamic Properties of 1H-Pyrazole-4-Carboxylic Acids in the Solid State

  摘要：

  三种简单的未在1号位取代的吡唑-4-羧酸结构（NH 衍生物）1H-吡唑-4-羧酸（1）、3(5)-甲基-1H-吡唑-4-羧酸（2）和3,5-二甲基-1H-吡唑-4-羧酸（3）基于晶体学结果（两个新结构）和固态核磁共振（CPMAS）进行讨论。化合物1和3具有多晶性，每种化合物的一个多形体显示固态质子转移（SSPT）。化合物2表现出已通过核磁共振研究的互变异构体，固态和在低温溶液中均有研究。

  DOI：

  10.1524/zpch.2013.0377
• 作为产物：
  描述：

  3-ethoxycarbonyl-3-penten-2-one 在 一水合肼 作用下， 生成 3,5-二甲基-1H-4-吡唑羧酸乙酯
  参考文献：
  名称：

  Knorr; Rosengarten, Justus Liebigs Annalen der Chemie, 1894, vol. 279, p. 237

  摘要：

  DOI：

文献信息

• [EN] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES<br/>[FR] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES
  申请人：BAYER AG

  公开号：WO2021028382A1

  公开（公告）日：2021-02-18

  The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）中R1、R2、R3、R4、R5、R6、R7和R8如所定义的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或与异常AHR信号传导相关的疾病，或与失调免疫反应或其他与异常AHR信号传导相关的疾病有关的情况，作为唯一药剂或与其他活性成分组合使用。
• PYRAZOL DERIVATIVES
  申请人：Aebi Johannes

  公开号：US20090029963A1

  公开（公告）日：2009-01-29

  The invention is concerned with novel pyrazol derivatives of formula (I), wherein R 1 , R 2 , R 3 , R 4 , X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.

  这项发明涉及式(I)的新型吡唑衍生物， 其中 R 1 ，R 2 ，R 3 ，R 4 ，X和Y如本文所定义，以及其生理上可接受的盐。这些化合物是CCR-2受体和/或CCR-5受体的拮抗剂，可用作药物。
• Tandem Aza Michael Addition–Vinylogous Nitroaldol Condensation: Construction of Highly Substituted <i>N</i>-Fused 3-Nitropyrazolopyridines
  作者：Owk Obulesu、V. Murugesh、Battu Harish、Surisetti Suresh

  DOI：10.1021/acs.joc.8b00746

  日期：2018.6.15

  A base-mediated tandem aza-Michael addition–vinylogous nitroaldol condensation has been described between 3,5-dialkyl 4-nitropyrazoles and alkynyl ketones/aldehydes. This transition metal-free atom economical transformation occurred via C–N and C═C bond formations in one step with the elimination of water. The construction of a variety of highly substituted N-fused 3-nitropyrazolopyridine derivatives

  3,5-二烷基4-硝基吡唑与炔基酮/醛之间存在碱介导的串联氮杂-迈克尔加成-乙烯基硝基醛缩合反应。这种无过渡金属的原子经济转变是通过消除水和一步形成C–N和C═C键而实现的。已经证明以高收率构建了多种高度取代的N-稠合的3-硝基吡唑并吡啶衍生物。用不对称取代的4-硝基吡唑已经实现了良好到优异的区域选择性。
• PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US20210078999A1

  公开（公告）日：2021-03-18

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物及其组合物。
• [EN] SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE 6- (1H-PYRAZOL-1-YL) PYRIMIDIN-4-AMINE SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：BAYER AG

  公开号：WO2018069222A1

  公开（公告）日：2018-04-19

  The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）所述和定义的取代6-(1H-吡唑-1-基)嘧啶-4-胺化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和组合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一活性成分或与其他活性成分组合使用，用于治疗和/或预防心血管和肾脏疾病。